News Hub | News Direct

CURE ALZHEIMER’S FUND APPOINTS TWO NEW MEMBERS TO ITS BOARD OF DIRECTORS

Alzheimer’s Disease Research Foundation

Cure Alzheimer’s Fund, a nonprofit dedicated to advancing research with the highest potential to prevent, slow or reverse Alzheimer’s disease, announced today that Christine Villas-Boas and Brittany Bowlen have been appointed to its Board of Directors. “We are pleased to welcome two new voices to our Board—Christine and Brittany each bring a unique passion and perspective that will help us better serve our mission to fund research aimed at curing Alzheimer’s disease,” said Henry McCance, Board Chair and Co-Founder of Cure Alzheimer’s Fund. “This expansion of our board is a meaningful step forward as we continue to grow thoughtfully and stay focused on making a lasting impact on the fight against this devastating disease.” “Brittany and Christine bring outstanding leadership expertise and a clear passion for our cause,” said Meg Smith, CEO of Cure Alzheimer’s Fund. “Their diverse experience in strategy and commitment to impactful philanthropy will enhance our efforts to accelerate critical research. We’re excited to welcome their insight and energy to our board.” Christine Villas-Boas currently serves as President and Treasurer of the Michel and Claire Gudefin Family Foundation, a leading supporter of Cure Alzheimer’s Fund. Ms. Villas-Boas, a Connecticut College graduate, began her career at Chase Manhattan Bank in 1974, working in U.S. Corporate Banking and International Capital Markets across New York, Paris, and London. She later consulted in credit and corporate finance training. Ms. Villas-Boas also serves on the board of the Learn2Earn Charitable Foundation based in Naples, Florida. Inspired by personal loss—her mother Claire, who died of Alzheimer’s in 2015, and other family members affected by the disease—Christine and the Michel and Claire Gudefin Family Foundation are deeply committed to supporting Cure Alzheimer’s Fund in its mission to find a cure. She became a Trustee in 2021 and joined the Board of Directors in 2025. Brittany Bowlen is a seasoned leader in consulting and professional sports, most recently serving as the Senior Vice President of Strategy for the Denver Broncos. In addition to her professional career, Brittany is deeply committed to driving community impact, currently serving as the Vice Chair of the Board of Directors for Boys & Girls Clubs of Metro Denver and as a member of the Board of Visitors for Duke University’s Fuqua School of Business. She holds a Master of Business Administration (MBA) from Fuqua and a Bachelor of Business Administration (BBA) from the University of Notre Dame’s Mendoza College of Business. Cure Alzheimer’s Fund is a nonprofit dedicated to funding the most promising research to prevent, slow or reverse Alzheimer’s disease. Since its founding in 2004, Cure Alzheimer’s Fund has provided 971 grants to more than 300 of the world’s leading researchers and contributed more than $232 million to research. Its funded initiatives have been responsible for many key breakthroughs in understanding the causes and pathology of Alzheimer’s disease. Cure Alzheimer’s Fund has achieved a 100% perfect score and a Four-Star rating for 13 consecutive years from Charity Navigator. Cure Alzheimer’s Fund also received a Platinum Seal of Transparency from Candid, formerly known as GuideStar. Our Board of Directors, Trustees and a core group of other donors direct their donations to our overhead expenses so that 100% of general donations go to our research program. For more information, visit CureAlz.org. Contact Details Barbara Chambers +1 978-417-9890 bchambers@curealz.org Company Website http://curealz.org

June 03, 2025 08:41 AM Eastern Daylight Time

CONSENSUS HEALTH’S ARNOLD PALLAY, MD FAAFP SELECTED AS A 2025 HEALTHCARE HERO BY NJBIZ MAGAZINE

Consensus Health

Consensus Health, a leading New Jersey-based healthcare organization with a physician-led medical group and an Independent Physician Alliance (IPA), announced today Arnold Pallay, MD FAAFP, practicing physician and medical director, was named a 2025 Healthcare Hero by NJBIZ Magazine, a leading business journal covering New Jersey. The Healthcare Heroes Awards program was created to recognize excellence, promote innovation and honor the efforts of individuals and organizations making a significant impact on the quality of health care throughout New Jersey. Submissions are reviewed and winners chosen by a panel of independent judges. The 2025 program recognized individuals and organizations across 10 categories. For nearly 40 years, Dr. Pallay has been a practicing family physician in the Montville, New Jersey community. In fact, he serves as volunteer president of the Montville Township Board of Health. Additionally, Dr. Pallay was chosen as the population health executive medical director for Partners In Care, the oldest IPA in New Jersey. Throughout his career, Dr. Pallay also garnered distinctive expertise in connective tissue, cardiac, neurodegenerative and pharmacogenetics (practiced by only a handful nationwide), prompting patients to travel from afar after experiencing struggles in their diagnoses and care. In all these roles, Dr. Pallay influences thousands of patients’ lives by assuring their top-notch quality care. “Having been selected as a 2025 Physician of the Year by NJBIZ is an exceptional and prestigious honor I am humbled to accept. Throughout my entire career, I have dedicated my practice to caring for generations of New Jersey families, and this award speaks volumes to the commitment I chose and my effects on local patient care. I thank the judges for acknowledging me, my patients for entrusting me and the Consensus Health Medical Group team for both recognizing and nominating me,” Dr. Pallay said. Michael Lovett, Consensus Health president and chief executive officer, added: “Dr. Pallay, one of the first physicians to join our medical group, has been impacting the health of New Jersey citizens for nearly four decades. During this time, he has excelled in his focus, always expanding his horizons to elevate care for families. All Consensus Health’s colleagues extend our deepest congratulations to Dr. Pallay on this prominent recognition and thank him for his unrelenting commitment to our patients.” NJBIZ Healthcare Heroes honorees will be recognized during an in-person awards ceremony on Tuesday, June 24 th, 8:00 AM – 10:30 AM at The Palace at Somerset Park in Somerset, NJ. Accompanying the event will be a publication supplement highlighting their accomplishments. The supplement will be inserted into the June 30, 2025 issue of NJBIZ. About Consensus Health Marlton, New Jersey-based Consensus Health is a leading physician-owned and -governed medical group comprised of New Jersey-based independent primary care providers and specialty doctors. Consensus Health affords its 172 member providers across 56 practices and 69 locations clinical autonomy, which enables them to focus on the delivery of high levels of patient care within the local markets they each serve. Currently, Consensus Health provides medical care statewide throughout 18 New Jersey counties. For more information, visit www.consensushealth.com or connect with the Company on LinkedIn. Contact Details PAIRELATIONS for Consensus Health Susan J. Turkell +1 303-766-4343 sturkell@pairelations.com Company Website https://www.consensushealth.com/

June 03, 2025 08:00 AM Eastern Daylight Time

Image

Inspira Technologies Receives $2 Price Target and Buy Rating: Everything You Need to Know

Global Markets News

Litchfield Hills Research has initiated coverage of Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN)* with a Buy rating and a $2 price target, representing potential upside of over 225% from current trading levels of around $0.61 per share. This bullish outlook comes as the medical technology company continues to critical care technology addressing what the analyst describes as "a medical need without good options." The analyst notes that mechanical ventilators are "WWII technology in desperate need of an upgrade" with reports showing that 30% to 50% of ICU patients don't survive. Unlike mechanical ventilation, Inspira's ART500 technology would enable patients to remain awake during treatment while stabilizing oxygen levels without intubation and coma. What distinguishes Inspira from typical early-stage medical device companies is its proven regulatory execution and early commercial success. The company's first generation technology, the INSPIRA ART100 system, received FDA clearance in May 2024 and is already deployed in leading U.S. hospitals. The excitement around this technology reached a new high in April 2025 when the first successful patient treatment was completed at Westchester Medical Center. The commercial momentum seems to be accelerating. Inspira announced it received payment in the "low hundreds of thousands of dollars" from its U.S. distributor for delivered systems, marking the company's first revenues. CEO Dagi Ben-Noon called this "a transformative milestone for Inspira as we establish our presence in the U.S. medical landscape." The company has now initiated global commercial rollout discussions and expects additional deliveries in the second half of 2025. Central to Inspira's technology platform is the AI-powered HYLA blood sensor, which recently achieved 96% accuracy in clinical studies at Sheba Medical Center, one of the world's top hospitals. The system provides continuous monitoring without requiring blood draws, targeting the blood gas analyzer market projected to reach $5.7 billion by 2030. The analyst identifies massive market opportunities, with the global mechanical ventilators market expected to reach $20.69 billion by 2034. Inspira's flagship INSPIRA ART500 system in development aims to disrupt this market by providing respiratory support through direct blood oxygenation rather than forcing air into damaged lungs. Inspira has established strong intellectual property protection with multiple U.S. patents and novel patent claims protecting its core technologies. The company is executing a strategic approach of securing FDA clearance for individual components before integrating them into comprehensive systems. When comparing Inspira to similar medical device companies, the analyst found the stock trades at significant discounts despite having FDA-cleared technology already treating patients. The $2 price target reflects confidence in the company's ability to capitalize on its early commercial success and expand into the massive mechanical ventilation market. The analyst concludes that Inspira may represents a unique opportunity, combining proven FDA-cleared technology with substantial market opportunity and attractive valuation metrics in the high-growth medical device sector. Recent News from Inspira: Inspira Technologies Initiates Global Commercial Rollout of FDA-Cleared ART100 System INSPIRA ART100 System Approved by Israel's Largest Healthcare Provider for Use in Organ Transplant Patients Inspira Achieves above 99% Gas Exchange Efficiency in VORTX™ Technology In-Vivo Animal Testing * Legal Disclaimer & Disclosure: Nothing in this article constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by the Wall Street Wire platform & media network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This article contains paid promotional content related to Inspira Technologies and was produced as part of their paid subscription to Wall Street Wire, which includes a monthly fee of five thousand US dollars paid in cash via bank transfer in return for promotional content and distribution services. The operators also receive additional fees for non promotional advisory and data services. Inspira Technologies did not necessarily review or approve this content prior to publication. Please review the full disclaimers and compensation disclosures here which include further details: redditwire.com/terms. We are not responsible for third party analyst price targets or market estimates are refer to them based on publicly availble reports. Additional or competing price target may exist and readers are advised to refer to the full report and its respective disclaimers and disclosures. Contact Details Wall Street Wire Editorial Desk media.globalmarkets@gmail.com

June 02, 2025 09:19 AM Eastern Daylight Time

Comcast to Connect 70,000 Homes and Businesses in Bryan-College Station to Reliable, Fiber Internet

Comcast Texas

Comcast will connect 70,000 new homes and businesses in Bryan-College Station to fast, secure and reliable, fiber Internet. This expansion into the region will enhance digital infrastructure, promote economic growth and position residents and local businesses for success in an increasingly digital world. The multi-year network expansion brings Xfinity and Comcast Business Internet, mobile, entertainment and security services to the two cities for the first time. The multiphase project includes building a new technology hub that will act as “the brain” of the network, supporting all Xfinity and Comcast Business services. Comcast will also install more than 1,000 miles of fiber lines – enough to span the distance from the Brazos Valley to Universal Studios in Florida. The tech leader also plans to open an interactive Xfinity retail store, which will be announced later. "Bryan-College Station is a hotbed for innovative technology, and this investment by Comcast will help our region stay competitive,” College Station Mayor John Nichols said. “Reliable broadband access is essential for our growing community, from the tens of thousands of Aggie students who call College Station home to our creative business community. Investing in strong connectivity ensures everyone has the advanced resources they need to thrive in a digital world." “We are grateful that Comcast is making this multimillion-dollar fiber infrastructure investment in our community,” City of Bryan Mayor Bobby Guiterrez said. “This investment in connectivity strengthens our local economy and helps our residents thrive. Expanding reliable high-speed Internet in Bryan will open doors for students, businesses and families. It will enhance opportunities and improve quality of life.” Residents can visit ComcastTexas.com/BCS for additional details on construction expectations and upcoming service availability. Portions of the project are currently under construction. Comcast’s most recent expansion to Bryan-College Station is part of the company’s $1.6 billion investment in technology and infrastructure in Texas over the last three years. “Expanding fiber Internet in communities like Bryan-College Station will be a catalyst for economic growth, enhancing educational opportunities and helping residents and businesses have the tools they need to thrive in the digital age,” Nicolas Jimenez, Comcast’s General Market Manager of Bryan-College Station said. “By investing in the infrastructure and connectivity of these communities, we’re empowering individuals and businesses to succeed and pave the way for a brighter, more connected future." A Network You Can Trust to be Reliable, Fast and Secure Comcast’s state-of-the-art network is built to enable residents and businesses to thrive in today’s constantly connected world. Bryan-College Station joins the 64 million homes and businesses across the country to have access to a network that is trusted by essential community organizations like hospitals, schools, transportation systems and first responders, and federal agencies like the Department of Defense. It delivers multi-gigabit Internet speeds, 99.9 percent reliability and security built in from the ground up to keep customers safe from cyber threats. Introducing Xfinity to Consumers Comcast’s residential services are marketed under the Xfinity brand. Consumers in Bryan-College Station will be able to take advantage of the full suite of Xfinity products: Internet, video, mobile, voice and home security. Xfinity offers multi-gigabit Internet speeds, powerful WiFi that reaches every corner of the home, and super-responsive, low-lag connections. Xfinity customers can enjoy a reliable, high-speed experience—whether they’re streaming sports and entertainment, video chatting with friends and coworkers, learning from home or simply browsing online. Comcast Business to Power Bryan-College Station’s Workforce For local businesses, Comcast Business offers a suite of connectivity, communications, networking, mobile, security, wireless, and managed solutions to help organizations of all sizes achieve their business goals. Industry analysts and associations have consistently recognized Comcast Business as a leader and innovator in flexible, scalable options as well as one of the fastest-growing providers of Ethernet services. Serving Everyone in the Bryan-College Station Community Comcast’s commitment to communities goes beyond building the network and aims to increase economic mobility for the local community and its residents. That’s why Comcast created Internet Essentials, a broadband adoption program that offers eligible households low-cost, high-speed Internet and affordable computers. Comcast Corporation (Nasdaq: CMCSA) is a global media and technology company. From the connectivity and platforms, we provide, to the content and experiences we create, our businesses reach hundreds of millions of customers, viewers, and guests worldwide. We deliver world-class broadband, wireless, and video through Xfinity, Comcast Business, and Sky; produce, distribute, and stream leading entertainment, sports, and news through brands including NBC, Telemundo, Universal, Peacock, and Sky; and bring incredible theme parks and attractions to life through Universal Destinations & Experiences. Visit www.comcastcorporation.com for more information. Contact Details Taisha Walker +1 832-942-1131 Taisha_Walker@comcast.com Company Website https://ComcastTexas.com/BCS

May 29, 2025 07:02 AM Central Daylight Time

Image

THE MAERCKS INSTITUTE: WHERE INNOVATION, ELEGANCE, AND ZERO-PAIN AESTHETIC SURGERY CONVERGE

The Maercks Institute

In a world where aesthetic procedures are increasingly sought after, patients are becoming more discerning—demanding not only exceptional results, but also safety, minimal downtime, and a truly elevated surgical experience. For over 15 years, The Maercks Institute in Miami has quietly set the gold standard for precisely this level of care. At its helm is Dr. Rian Maercks, a board-certified plastic surgeon with elite training from Duke University Medical Center and an international reputation for aesthetic innovation, safety, and elegance in results. Dr. Maercks’ expertise is not confined to the American academic tradition alone. His advanced surgical training and aesthetic experience span the globe—gaining exposure to the most prestigious and forward-thinking techniques across Europe, Central America, and South America. This global perspective informs his deeply nuanced understanding of beauty and anatomy across diverse cultures and aesthetic ideals, shaping the distinctive and tailored approach for which The Maercks Institute is known. Sophisticated patients from around the world turn to Dr. Maercks not only for his artistry, but for a singular promise: surgical excellence without pain, without opioids, and without the extended recoveries typically associated with aesthetic enhancement. EXAREL AND THE MAERCKS METHOD™: A BREAKTHROUGH IN PAIN-FREE, NO-DOWNTIME SURGERY The Maercks Institute offers something rarely found in aesthetic surgery today—a comprehensive array of aesthetic and corrective procedures performed with zero pain and often no need for post-operative narcotics. At the core of this revolutionary approach is Dr. Maercks’ proprietary integration of Exparel, an advanced, FDA-approved, liposomal formulation of bupivacaine that slowly releases local anesthetic over 72 hours. By combining this with his proprietary tumescent Exparel technique—which includes careful dilution, epinephrine augmentation, and a deep understanding of the gate control theory of pain—Dr. Maercks delivers procedures from deep-plane facelifts to breast augmentations with unprecedented patient comfort. Patients receive a full regional nerve block using Exparel before any incision is made. Even when general anesthesia is employed, the body is completely anesthetized locally, preventing the brain from registering pain signals both during and after surgery. The result? Patients consistently awaken feeling as though they haven't had surgery at all. They walk out of the Institute unaided, smiling, and often singing—as documented in hundreds of post-op videos at @themaercksinstitute. Remarkably, patients undergoing facelifts, body contouring, and complex revision surgeries at The Maercks Institute routinely report needing no opioids such as Percocet, no extended recovery period, and no memory of discomfort—just beautiful, natural-looking results. NATURAL REJUVENATION WITHOUT THE TELL-TALE SIGNS: THE MAERCKS LIFT As recently highlighted by the American Society of Plastic Surgeons in their article "The Mid-Facelift is Taking Facial Aesthetics by Storm", the modern patient is seeking discreet rejuvenation with minimal interruption to their lives. In response, Dr. Maercks has pioneered the MAERCKS Lift, a deep-plane midface and lower face rejuvenation technique that restores natural contours without distortion or downtime. Unlike superficial “skin pulling” methods or trendy, temporary fixes, the MAERCKS Lift works by re-supporting the deeper tissues of the face and midface along natural vectors of aging. This allows for a profoundly youthful result without the overly tight or artificial appearance seen in many conventional facelifts. Because of his innovative approach, Dr. Maercks is widely considered the go-to expert for patients desiring subtle yet significant rejuvenation. Importantly, Dr. Maercks also emphasizes holistic harmony: “A rejuvenated face must be seen in context,” he explains. “Neglecting the neck or jawline creates disharmony that patients intuitively recognize. That's why I often integrate micro-lifting or lateral platysmaplasty techniques—even in minimally invasive cases—without adding downtime or discomfort.” THE MAERCKS INSTITUTE EXPERIENCE: DISCRETION, EXCELLENCE, AND GLOBAL RECOGNITION Discerning patients seeking surgical or non-surgical facial rejuvenation, breast and body enhancement, or revision procedures find in The Maercks Institute a sanctuary of both advanced science and aesthetic artistry. With a concierge-style approach to care, elite surgical techniques, and an unwavering focus on safety and sophistication, the Institute attracts a global clientele of business leaders, public figures, and patients who value discretion and excellence. Dr. Maercks’ broad and prestigious international training through Europe, Central America, and South America allows him to draw from a uniquely diverse foundation of aesthetic understanding. This international influence has been a key driver in developing his signature techniques—each refined to prioritize safety, individuality, and natural elegance. With over 15 years in private practice, hundreds of zero-downtime success stories, and an ongoing commitment to pushing the field forward, he has earned his reputation as a trusted authority in the evolving world of plastic surgery. SCHEDULE A PRIVATE CONSULTATION For patients who value both innovation and elegance—and who are unwilling to compromise on safety or recovery—The Maercks Institute offers a uniquely refined path to self-enhancement. Discover what it means to undergo a procedure without pain, without opioids, and without sacrifice. To schedule a private consultation or learn more about our services, visit www.themaercksinstitute.com or contact the Institute directly at (305) 328-8256. Contact Details Courtney Daniels Consulting Courtney Daniels courtney@cocodaniels.com Company Website https://www.themaercksinstitute.com/

May 27, 2025 10:00 AM Eastern Daylight Time

Centre for Neuro Skills Chief Financial Officer Named 2025 Kern County Heart Walk Chair

Centre for Neuro Skills

Lindsay Ashley, chief financial officer of Centre for Neuro Skills, has been named chair of the American Heart Association ’s 2025 Kern County Heart and Stroke Walk. The annual event is scheduled for Saturday, Oct. 11, at California State University, Bakersfield. “The Kern County Heart and Stroke Walk is an opportunity to celebrate heart disease and stroke survivors, raise lifesaving funds for the American Heart Association and encourage a healthy lifestyle,” said Ashley. “By bringing the community together to raise awareness and funds to fight heart disease and stroke, we’re making strides to ensure our loved ones can live longer, healthier lives.” Ashley will lead a team of Kern County-area executives to recruit companies and organizations to take part in the Heart and Stroke Walk. The leadership team and supporting organizations will raise funds for the American Heart Association while leading action-oriented conversations about employee health, corporate engagement, community health and community transformation. The American Heart Association is the world’s leading non-profit dedicated to a world of healthier lives for all. In addition to Ashley, the 2025 Kern County Heart and Stroke Walk executive leadership team includes: David Harrington, Centre for Neuro Skills Didra Cantu, MPA-HCM, Encompass Health Rehabilitation Hospital George Jenkins, Dignity Health, Bakersfield Memorial Hospital Ken Keller, Dignity Health, Bakersfield Memorial Hospital Kevin Burton, Klein DeNatale Goldner Lindsay Barnes, KGET-TV 17 Lisa Kreber, PhD, CBIS, Adventist Health Bakersfield Scott Salters, Cushman & Wakefield | Pacific Commercial Realty Advisors Sky Newton, SHRM-CP, Valley Strong Credit Union "The Heart and Stroke Walk is a fantastic chance for Kern County to come together as a united community, standing strong against heart disease and stroke," said Kelley Berry, executive director of the American Heart Association, Kern County. "We are immensely grateful for Lindsay's steadfast expertise, passion, and dedication to our mission. Leaders like her are crucial in our ongoing efforts to save lives and provide hope to families affected by heart disease and stroke." Funds raised go toward the American Heart Association’s work to advance lifesaving research, education and health for everyone. In Kern County, the Association has expanded access to CPR skills, connected local heart and stroke patients to the latest science-based treatments through its hospital programs and supported community members managing high blood pressure with tools and resources for better blood pressure control. Heart disease and stroke are largely preventable and how you eat, move and manage stress impacts your well-being, physically and mentally. Participants in the Heart and Stroke Walk gain access to resources, tools and activities to support both mental and physical well-being for employers and employees. Participants can register for the event at BakersfieldHeartWalk.com. Registrants can also create personal fundraising pages, download the Heart Walk mobile app and encourage family and friends to join. Companies interested in participating can contact Kelley Berry at Kelley.berry@heart.org. Centre for Neuro Skills, with seven locations across California and Texas, will be participating in American Heart Association’s local heart walk events across both states. Dr. Matt Ashley, Chief Medical Officer of Centre for Neuro Skills, currently serves as Board President on the Central Texas American Heart Association’s Board of Directors and will transition to Board Chair this July. As a former Heart Walk Chair in Austin, Texas, Dr. Matt Ashley remains committed to participating in and supporting the Central Texas Heart Walks. *** About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public’s health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with the American Heart Association in Kern County on heart.org/southern-california, Facebook, Instagram, X or by calling 1-800-AHA-USA1. About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. For a video overview of CNS, visit our YouTube channel. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. ### Contact Details Landis Communications Inc. Andie Davis +1 415-766-8355 cns@landispr.com Company Website https://www.neuroskills.com/

May 20, 2025 08:01 AM Pacific Daylight Time

Image

News Release

4 Stocks To Watch In The $47 Billion Cellular Therapeutics Market

ADIA FATE DNA PLUR

Cell-based therapeutics have come a long way from simply experimental treatments confined in labs to their current mainstream commercial success. In the past year alone, the FDA approved seven new cell therapies, bringing the total number of gene and cell therapies approved in the US to 43, with the largest segment of these products being umbilical cord blood derivatives. Unlike other treatments, cell-based therapies use modified or healthy cells to treat or prevent disease, often by replacing damaged or malfunctioning cells. This makes cell-based therapies uniquely suited for various conditions like cancer treatments, autoimmune disorders, and tissue regeneration. Thanks to the rapidly advancing pace of innovation and cell therapy’s potential to transform across disease areas with significant unmet needs, market researchers project that the global cell therapy market could grow from about $7.43 billion in 2025 and reach around $47.72 billion by 2034, representing an impressive CAGR of 22.96% over the period. As such, a number of key players in the market have been generating considerable investor interest as they continue increasing market share. For instance: Adia Nutrition Inc. (OTCQB:ADIA) is on a mission to revolutionize healthcare and supplementation through innovative partnerships. The company operates two distinct divisions: Adia Labs, a supplement division providing premium, organic supplements, and Adia Med, its medical division responsible for establishing clinics that specialize in leading-edge stem cell therapies, most notably Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) for treatments like Multiple Sclerosis (MS). Adia has recently been generating significant investor interest following an exciting start to the year with the announcement of several major corporate milestones. In May, the company announced that it had successfully uplisted from the OTC Pink Sheets to the OTCQB Venture Market, effectively enhancing its visibility and liquidity. The process was achieved in an unprecedented six weeks from the filing date of April 2nd, alongside the completion of SEC Rule 15c2-11 compliance. The OTCQB Venture Market and 15c2-11 compliance elevate Adia's ability to showcase its pioneering umbilical cord stem cell therapies and premium nutritional products to a wider investor base, potentially unlocking more shareholder value. The uplisting follows the successful completion of its independent audit, a crucial milestone that positioned the company for uplisting to the OTCQB. Earlier, Adia had announced a transformative overhaul of its share structure, including the retirement of approximately 15 million shares, reducing the outstanding common stock from about 95.9 million shares to 80.4 million shares, and the cancellation of a commitment agreement requiring the issuance of 10 million additional shares. Furthermore, the company recently revealed that Adia Labs had secured FDA registration for Adia Vita, one of its top-tier products featuring umbilical cord stem cells with a minimum of 100 million viable cells and 3 trillion exosomes per unit, in a move that would expand the reach of its regenerative treatments. By offering a superior product at a reduced price, Adia Med intends to differentiate itself from existing alternatives, thereby driving rapid client growth and making these therapies more accessible. At the beginning of the year, Adia set out an ambitious strategic expansion plan for Adia Med satellite locations across the United States. This initiative aimed to make Adia Med's innovative treatments more accessible by partnering with premier medical spas dedicated to anti-aging, wellness, and body repair. In line with this plan, the company announced the opening of its first satellite location in Tinton Falls, New Jersey. This was in partnership with Keep Glowing Medical Spa and renowned physician Dr. Michael Ellis, thus blending cutting-edge stem cell therapies with an established wellness hub. It is also important to note that Adia is in the process of registering with the State of Florida's Agency for Health Care Administration (AHCA), a crucial initiative designed to secure approval for accepting private insurance for the company’s stem cell therapies. Until now, Adia Med's operations have depended solely on out-of-pocket payments from patients. However, that approval could be a game changer since collaborating with private insurers would lift the financial barriers that currently restrict patient access. Unsurprisingly, several organizations and healthcare entities from various countries have reached out to Adia Med over recent months, expressing enthusiasm for establishing clinics that offer its cutting-edge treatments, including therapeutic plasma exchange (TPE), hematopoietic stem cell transplantation (HSCT), and umbilical cord blood stem cell (UCB-SC) therapies utilizing Adia Labs' premier product, Adia Vita. Fate Therapeutics (NASDAQ:FATE) is focused on developing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies. The company’s proprietary iPSC product platform is uniquely designed to facilitate the manufacture of engineered cell products, which can be stored in inventory for off-the-shelf availability and can be administered in combination with other therapies. This therefore allows it to overcome numerous limitations associated with patient- and donor-sourced cell therapies. FATE recently announced that the FDA had granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead product, FT819, illustrating the potential of cell-based therapies. FT819 is an investigational, off-the-shelf, iPSC-derived CAR T-cell therapy that is currently in Phase 1 clinical development for the treatment of active moderate to severe systemic lupus erythematosus (SLE), including lupus nephritis (LN). What the RMAT designation means is that the FDA recognizes the potential of off-the-shelf CAR T-cell therapy to address significant unmet needs and will enable increased dialogue with the FDA throughout the development process. The RMAT designation was established to expedite the development and review of regenerative medicine therapies for serious or life-threatening diseases or conditions. The designation includes all Breakthrough Therapy designation features, such as early interactions with the FDA, including discussions on potential surrogate or intermediate endpoints that may support accelerated approval and satisfy post-approval requirements, and potential priority review of a product’s biologics license application. Pluri Inc. (NASDAQ:PLUR) is a leading biotechnology company leveraging its proprietary platform to create cell-based solutions that will revolutionize everything from the way we treat illness to the way we eat. Pluri’s 3D cell expansion platforms can expand a single cell into billions of distinct cells quickly and reliably, in a highly cost-effective process that can be applied to various types of cells. The company recently achieved a significant milestone after the US Patent and Trademark Office (USPTO) issued a patent for its immune cell expansion technologies. The patent covers mucosal-associated invariant T (MAIT) cells, which play a crucial role in the body's defense against infection and support tissue repair. Pluri’s placental allogeneic MAIT cell platform facilitates the development of unconventional immune T cells that could be instrumental in treating solid tumors. This is important considering that despite revolutionary progress in blood cancers, equivalent success has yet to be duplicated in solid tumor malignancies, which present unique challenges. Pluri’s MAIT cells, which are isolated from human placentas, a source rich in highly potent allogeneic immune cells often overlooked in traditional therapies, offer substantial benefits compared to conventional T cells. Unlike conventional T cells typically collected from peripheral blood, Pluri’s MAIT cells demonstrate a lower alloreactivity profile. This characteristic not only minimizes their likelihood of inducing graft-versus-host disease (GvHD)—a significant advantage over other potential allogeneic products—but also suggests that they may persist in the body for a longer duration, enhancing their therapeutic efficacy. Ginkgo Bioworks (NYSE:DNA) is building one of the leading horizontal platforms for cell programming and biosecurity. This cell programming platform enables the growth of biotechnology across diverse markets, from food to fragrance to pharmaceuticals. The company recently reported its first-quarter earnings, with total revenue coming in at $48 million, up from $38 million in the comparable prior-year period. This reflected a 27% increase primarily due to $7 million of non-cash revenue from deferred revenue relating to the mutual termination of a customer agreement. Excluding the $7 million non-cash deferred revenue release, first-quarter cell engineering revenue was $31 million, up from $28 million in the prior-year period. During the earnings call, management reiterated that biotechnology remained a critical emerging technology area in the US and Ginkgo was well positioned to provide biosecurity and R&D services, as illustrated by its 28 US government projects across cell engineering and biosecurity with roughly $180 million of contracted backlog and unfunded potential backlog. In addition, the company noted that it had made significant progress on cost cutting while still serving its customers. Gingko revealed that it was on track for a $205 million reduction in its annual run rate between the first quarter of 2024 and the first quarter of this year. Cash, cash equivalents, and marketable securities balance as of the end of the period were $517 million. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by the company to assist in the production and distribution of content related to ADIA. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com

May 20, 2025 06:00 AM Eastern Daylight Time

Market Alert: DarioHealth Receives $3 Price Target and Buy Rating: Everything You Need to Know

Global Markets News

Litchfield Hills Research has initiated coverage of DarioHealth Corp. (NASDAQ: DRIO)* with a Buy rating and a $3 price target, representing potential upside of over 350% from current trading levels of around $0.66 per share. This bullish outlook comes as the digital health company continues to transform its business model and expand its comprehensive chronic care platform. DarioHealth has successfully pivoted from a direct-to-consumer model to a B2B2C (business-to-business-to-consumer) approach since 2020. This strategic shift has allowed the company to leverage its consumer platform strengths while expanding sales to health plans and employers. The company's B2B2C recurring revenue grew by an impressive 398% year-over-year in Q4 2024, demonstrating strong market adoption. The analyst highlights Dario's proven track record of both organic growth and strategic acquisitions, including the recent Twill acquisition which has strengthened its multi-condition platform. This expansion has positioned Dario to address five of the most common, expensive chronic conditions through a single, integrated solution. The $3 price target is based on a discounted future earnings model with a 9% discount rate. The analysis assumes Dario will reach GAAP breakeven in the second half of 2026, continue strong revenue growth to reach $66.1 million in 2026, achieve non-GAAP operating income of $17.4 million in 2026, and show improving gross margins, exceeding 80% in its core B2B2C business. Importantly, the report demonstrates that even at the $3 target price, Dario would trade at approximately 2.2x projected 2026 sales, which is still below the peer average of 2.28x. The analyst suggests Dario should command a premium multiple given its high growth profile and comprehensive platform. The report highlights Dario's unique competitive advantages relative to peers in the digital health space. Unlike competitors who focus on single conditions, Dario offers a comprehensive platform addressing diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. When comparing current market cap to sales and enterprise value to sales multiples, Dario trades at substantial discounts – 81% below peers on market cap to sales ratio and 54% below peers on enterprise value to sales ratio. This valuation gap, combined with Dario's proven clinical outcomes and expanding market presence, forms the core of the analyst's bull case. A significant growth driver highlighted in the report is Dario's expansion into the GLP-1 weight management space. The company's research has shown that members using GLP-1 experienced significant reductions in blood glucose levels in the first five months with changes sustained throughout the year. With the GLP-1 market projected to reach $100 billion by 2030, Dario's comprehensive solution combining medication management with behavioral support positions it to capture market share in this rapidly growing segment. Strategic partnerships, including its recent collaboration with Rula Health, further strengthen Dario's offering by providing access to over 15,000 behavioral health providers nationwide. The company is also leveraging AI technology to reduce operating expenses, with projections suggesting a 20% reduction in expenses between Q4 2024 and Q4 2025 through AI-driven process optimization. Litchfield Hills projects Dario's revenue will grow to $35.9 million in 2025 and $66.1 million in 2026, with gross margins improving to nearly 70% by 2026. The company is expected to achieve operational cash flow breakeven by late 2025, with full profitability in the second half of 2026. The recent $25.6 million private placement has strengthened Dario's balance sheet, providing sufficient runway to execute its strategic plan. With a blue-chip client list that includes major employers like Amazon, Microsoft, and Google, as well as top insurers and pharmaceutical companies, Dario appears well-positioned to capitalize on the growing demand for integrated digital health solutions that deliver measurable clinical outcomes and positive ROI. Recent News from Dario: DarioHealth Reports First Quarter 2025 Financial and Operating Results Dario's Digital Health Solution Demonstrates Effectiveness in New Research Examining Flu Vaccination Awareness in High-Risk Populations DarioHealth Closes Strategic Refinancing of Existing Debt Facility of up to $50 Million to Provide Additional Operational Flexibility and Support Growth Initiatives * Legal Disclaimer & Disclosure: Nothing in this article constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by the Wall Street Wire platform & media network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This article contains paid promotional content related to DarioHealth and was produced as part of their paid subscription to Wall Street Wire, which includes a monthly fee of five thousand US dollars paid in cash in return for promotional content and distribution services. The operators also receive additional fees for non promotional advisory and data services. DarioHealth did not necessarily review or approve this content prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms. We are not responsible for third party analyst price targets are refer to them based on publicly availble reports. Additional or competing price target may exist and readers are advised to refer to the full report and its respective disclaimers and disclosures. Contact Details Wall Street Wire Network media.globalmarkets@gmail.com

May 19, 2025 07:51 AM Eastern Daylight Time

IntusCare Announces PACE Organization of Rhode Island is First to Deploy Innovative EMR and Practice Management System Platform

Intus Care

IntusCare, a technology leader in the PACE market, today announced that PACE Organization of Rhode Island (PACE-RI) has officially gone live with IntusCare CareHub, an EMR and practice management system built for PACE’s value-based care model. PACE-RI is one of the nation’s most innovative Programs of All-Inclusive Care for the Elderly (PACE). The successful launch marks a major milestone in a years-long partnership between the two organizations that has been defined by co-creation, trust, and an implementation model centered on deep collaboration. To prepare PACE-RI for the launch, IntusCare delivered a fully immersive, white-glove implementation for PACE-RI, reflecting its commitment to long-term success. The support included in-person workflow discovery sessions with operational subject matter experts and super users, as well as twice-weekly SOP alignment meetings to evolve internal processes alongside CareHub’s capabilities. IntusCare also led a four-day, on-site training bootcamp spanning multiple PACE-RI centers and conducted weekly readiness scoring calls with PACE-RI leadership. During go-live, the team implemented a three-day, center-wide support structure and ensured hands-on involvement from IntusCare’s product team throughout every stage of the process. “This wasn’t just a rollout, it was a joint effort to reimagine how our teams work and collaborate,” said Joan Kwiatkowski, MSW, Chief Executive Officer at PACE-RI. “What excites us most about CareHub is that it’s built for PACE, with PACE. From the start, it’s been thoughtfully designed around the unique needs of our model. We’re confident it will help us operate more efficiently and stay better connected across teams.” In the months ahead, CareHub is expected to deliver measurable gains in interdisciplinary team coordination, reduce documentation time, and improve visibility across clinical and operational workflows. “The ability to link CareHub with other IntusCare products like IRIS and Analytics creates a powerful, all-in-one solution for our clinical and administrative teams,” said Liz Boucher, Chief of Organizational Performance at PACE-RI. CareHub will help us work more efficiently and reduce the burden on staff, creating a happier workforce and freeing up time to focus on caring for our participants. And when we can spend more time with participants, we see better outcomes—especially when paired with easier access to key data that enables earlier, more effective interventions.” PACE-RI’s leadership and frontline staff have played a foundational role in the development of CareHub through their work on the CareHub Product Steering Committee, whose input has directly shaped features like IDT tasking tools, intuitive care planning modules, and embedded compliance support. That collaboration will continue as PACE-RI expands its use of CareHub and helps guide future enhancements. “As our first partner, PACE-RI has helped us build something truly transformative for the PACE community,” said Robbie Felton, Chief Executive Officer at IntusCare. “This go-live isn’t just the culmination of a product build—it’s the start of a new era in how technology supports participant care.” About IntusCare ‍IntusCare is the only end-to-end ecosystem built specifically to help PACE programs deliver exceptional care, strengthen financial performance, and stay compliant. IntusCare replaces outdated technology and manual workaround with purpose-built tools for care coordination, risk adjustment, population health, and utilization management. IntusCare empowers teams to take control of their operations and improve outcomes for dual-eligible seniors – some of the most socially vulnerable and clinically complex individuals in the U.S. healthcare system. Visit our website to learn more intuscare.com. About PACE-RI PACE-RI is the non-profit health plan for adults 55 and older who are nursing home eligible but wish to remain living at home. PACE-RI provides both insurance and medical care, as well as a range of health and social services that include adult day care, transportation, and meals. Taking a comprehensive approach to well-being, PACE-RI is able to keep its medically complex participants in the community for an extra four years on average. With center locations in East Providence, Newport, Westerly, and Woonsocket, PACE-RI’s 200 employees serve the entire state. The Program of All-inclusive Care for Elders is a federally designated model overseen by CMS that is now in 33 states serving 80,000 participants. Learn more: PACE Organization of Rhode Island | Services for the Elderly Contact Details SVM Public Relations +1 401-490-9700 intuscare@svmpr.com Company Website https://www.intuscare.com/

May 14, 2025 10:00 AM Eastern Daylight Time